Serapha Bio
Serapha Bio is a biotech company in San Diego, United States, founded in 2026. It has raised $138.0M across 1 round, most recently a $138.0M Series A in June 2026.
Gene editing to cure alpha-1 antitrypsin deficiency
- Headquarters
- San Diego, California
- Employees
- 1–10
- Founded
- 2026
- Business Model
- B2B
- Website
- seraphabio.com
- Total Funding
- $138.0M
- Last Round
- $138.0M Series AJun 2026
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 1 funding round and 2 investors for this company. The full record is or through the API.
About
Serapha Bio is developing SERP-01, a proprietary in vivo base editing program currently in a Phase 1/2 clinical trial for the treatment of AATD with the PiZZ genotype. SERP-01 is designed to restore production of functional M-AAT while reducing toxic Z-AAT, with the potential to address both the liver and lung manifestations of AATD with a single intravenous administration.
Summary
It lists 1–10 employees. It has raised $138.0M in total across 1 round, most recently a $138.0M Series A round in Jun 2026. Investors include RA Capital Management and RTW Investments.
Funding History
Jun 2026
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/serapha-bio"><img src="https://indexed.vc/api/badge/company/serapha-bio" alt="Serapha Bio on Indexed.vc" width="260" height="76" /></a>